General literature
Reverse Design toward Optimized Labeled Chemical Probes – Examples from the Endocannabinoid System

Guberman M., Kosar M., Omran A., Carreira E. M., Nazaré M., Grether U.

CHIMIA Medicinal Chemistry 2022, Vol. 76 No. 5

DOI
General literature
PROTACs Developed with U. of Dundee Boost Boehringer Ingelheim's Cancer Pipeline

Philippidis A.

Gen Edge 2019, VOL. 1, NO. 1.

DOI
Success examples
The inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach

Agosile O. O., Njoku P. C., Oduwe U., Aremu A. J., Fajobi S. J., Akachukwu S. O., Adebisi A. R., Abolaji A. O., Omirin E. S.

Research Square 2023, PREPRINT (Version 1).

KRAS switch I/II pocket inhibitor
DOI
Success examples
Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins

Bond A. G., Craigon C., Chan K., Testa A., Karapetsas A., Fasimoye R., Macartney T., Blow J. J., Alessi D. R., Ciulli A.

J Med Chem. 2021, 64(20):15477-15502.

BET PROTAC
DOI
PubMed
Success examples
Novel GLP-1 secretagogues as neuroprotective agents for retinal neurodegenerative diseases

Powell F. L., Thomas S., Martin P. M.

Invest. Ophthalmol. Vis. Sci. 2023, 64(8):1842.

GPR142 Agonist
DOI
Success examples
A cathepsin C-like protease mediates the post-translation modification of Toxoplasma gondii secretory proteins for optimal invasion and egress

Thornton L. B., Key M., Micchelli C., Stasic A. J., Kwain S., Floyd K., Moreno S. N. J., Dominy B. N., Whitehead D. C., Dou Z.

mBio 2023, e0017423. Epub 2023 Jun 16.

DPAP1 Inhibitor
DOI
PubMed